Mark A. Turco, MD, FACC
President & CEO
A Healthcare and business executive with 30+ years of academic, private, and public sector expertise spanning Interventional Cardiology, two-large-cap companies, novel technology discovery and translation and operating roles. Dr. Turco was appointed President & CEO of Cardiac Implants LLC in July 2022. He was able to solidify a 13.5M investment round to help advance a US based EFS trial along with further R&D efforts of its Tri-Ring™ device. Previously while at Covidien, Dr. Turco was instrumental in helping to build Covidien’s vascular platform, which was subsequently a key component of Medtronic’s $42B acquisition of Covidien. Dr. Turco spent many years after his time at Medtronic in the academic sector leading innovation efforts at the University of Pennsylvania, Philadelphia, PA. as their Chief Innovation officer. Dr. Turco was instrumental in the develop of Penn’s medical device center (Penn Health-Tech) connecting medicine and engineering helping to facilitate the two schools producing numerous spin out companies and building important industry and academic collaborations. After his time at Penn he led R&D and medical/clinical activities at Sirtex Medical as the Global Chief Medical Officer and EVP R&D in the field of Interventional Oncology facilitating Global evidence generation and adoption of Sirtex’s radio-embolic technology. Dr. Turco was the Director, Center for Cardiac and Vascular Research at Washington Adventist Hospital in Maryland before transitioning to the medical device industry.